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ABSTRACT 
Accumulating evidence suggests that rheumatoid arthritis (RA) is a T-cell mediated 
autoimmune disease. Early attempts at disease modulation using strategies such as 
CD4 monoclonal antibodies (mAbs) were severely hampered by a lack of biomarkers 
of autoreactivity. Recently, however, costimulation blockade has emerged as an 
effective treatment for RA. Alongside a greatly improved mechanistic understanding 
of immune regulation, this has rekindled hopes for authentic and robust immune 
programming. The final pieces of the jigsaw are not yet in place for RA but, in other 
disciplines, emerging treatment paradigms such as non-mitogenic anti-CD3 mAbs, 
autoantigenic peptides, and even cellular therapies are providing hope for a future in 
which immunopathology can be specifically and vigorously curtailed. 
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INTRODUCTION 
Models of rheumatoid arthritis (RA) pathogenesis have undergone several major 
revisions since the discovery of rheumatoid factor (RhF) spawned a model focussed 
on B-cells and immune complexes [1]. Subsequently T-cells took centre stage [2], 
only to be usurped by models focussed on cytokine dysregulation [3]. Recently a B-
cell resurrection has taken place [4] but most now accept a complex pathogenetic 
model incorporating multiple aspects of innate and acquired immunity, whose relative 
contribution varies according to disease stage and probably between patients. 
Targeted therapies and associated pharmacogenetic analyses  will play an important 
role in unravelling the complex pathological tapestry of RA [5]. This review will focus 
on the likely role of T-cells, and their potential for therapeutic manipulation. 
 
EVIDENCE FOR T-CELL INVOLVEMENT IN RA 
T-cells are one of the most abundant cell types in RA synovium, comprising 30-50% 
of synovial tissue cells [6]. The majority are CD4+, although CD8+ T-cells are also 
present and may be of pathogenic importance [7]. A significant contributor to the 
demise of the T-cell model of RA was the paucity of TH1-type cytokines in the 
rheumatoid synovium. The discovery of T-cell subsets led to immunopathological 
paradigms characterised by ‘immune deviation’ away from a healthy balance of T-cell 
derived cytokines. TH2 excess (IL-4, IL-5, IL-10) underpinned allergic or ‘humoral’ 
diseases such as atopic eczema and asthma, whereas TH1 excess was implicated in 
cellular pathologies such as diabetes, multiple sclerosis and RA. However, levels of 
T-cell cytokines, such as interferon gamma (IFN-γ) and interleukin-2 (IL-2), were low 
in RA synovium in contrast to monokines such as TNF-α and macrophage colony 
stimulating factor (M-CSF) [8]. It was subsequently demonstrated that synovial T-
cells activated macrophages via membrane interactions [9] but, at the time, a dogma 
evolved that T-cells were merely innocent bystanders in RA synovium, attracted by 
the inflammatory milieu. Recently IL-17, produced by imaginatively named TH17 T-
cells, has been implicated in human autoimmune inflammation [10]. Although 
discovered some 10 years ago, a potentially key role in diseases such as RA has 
only recently been attributed to IL-17 [11]. TH17 T-cells mature from naïve T-cells, 
and survive, in an environment characterised by IL-6, TGFβ and IL-23 [12]. IL-17 is a 
highly pleiotropic cytokine with effects on a variety of cell types including monocytes, 
fibroblast-like synoviocytes, chondrocytes and osteoclasts. Direct or indirect effects 
include inflammation, angiogenesis, osteoclastogenesis, and breakdown of bone and 
cartilage. A number of studies have demonstrated elevated levels in blood and 
synovium of RA patients, with correlations between synovial levels and joint damage. 
[13-15]. Nonetheless, the biology of TH17 cells differs in important ways between 
mouse and human and the relative contribution of TH1 and TH17 T-cells to RA 
pathogenesis remains to be formally established [16-19]. 
 
Recent studies of genetic predisposition to RA have bolstered evidence for T-cell 
involvement in its pathogenesis. For many years, the only consistent genetic linkage 
was with the HLA-DRβ1 locus. Alleles containing the so-called ‘shared epitope’ at 
residues 70-74 associated with more severe RA, and a ‘double dose’ with an even 
worse prognosis [20]. Although this locus underpinned class II HLA polymorphism, 
and therefore guided the presentation of foreign and self antigens to T-cells, 
consistent autoreactivity to potential autoantigens proved surprisingly difficult to 
demonstrate. Recently, more powerful genetic studies have implicated the gene 
PTPN22 in RA predisposition [21]. There is weaker evidence linking CTLA-4 [22]. 
PTPN22 helps to set T-cell activation thresholds, whereas CTLA-4 downregulates 
activated T-cells – critical determinants of T-cell responses to foreign antigens but 
also for both central and peripheral tolerance to self antigens. Recent epidemiologic 
studies have incorporated these genetic factors into credible models of RA aetiology. 
Cigarette smoking, which increases the rate of protein citrullination in the lung, 
appears to predispose to anti-CCP autoantibody development in individuals who 
carry the shared epitope [23]. Anti-CCP autoantibodies associate with destructive RA 
[24] although are also found in healthy individuals prior to the onset of synovitis [25]. 
An individual’s relative risk of developing RA is further heightened if they carry the 
RA-linked PTPN22 allele. Indeed, in some (although not all) populations, the most 
adverse set of factors are associated with a relative risk of developing RA of 20-25 
times background [26,27]. Furthermore, the gene encoding peptidyl arginine 
deiminase 4 (PADI4), an enzyme responsible for citrullination of proteins, has been 
associated with RA in studies of Asian populations, although inconsistently in 
Europeans [28-30]. These data significantly strengthen the case for T-cell 
involvement in RA, at least in the early stages of anti-CCP positive disease.  
Additionally, STAT4 is a transcription factor downstream of both the IL12 and IL23 
receptors on T-cells, whose target genes include both interferon-γ and IL-17. Recent 
studies have implicated the gene encoding STAT-4 in RA susceptibility in North 
American, European and Asian populations [31,32].  
 
The aetiological factors implicated in anti-CCP positive RA do not appear to 
predispose to anti-CCP negative RA [26]. Whilst this may seem to reduce the 
likelihood of T-cell involvement in those patients, no alternative aetiological models 
currently exist. The fact that RA T-cells are hypo-proliferative, or anergic, is one 
factor that has complicated attempts to demonstrate T-cell autoreactivity [33,34]. 
However, assays that rely on T-cell cytokine secretion rather than proliferation have 
started to show consistent examples of autoreactivity. For example, T-cell responses 
against the cartilage (auto)antigen human glycoprotein (hGP)-39 are associated with 
production of immunoregulatory IL-10 in DRβ1*04-positive healthy controls but pro-
inflammatory cytokines in DRβ1*04-positive RA patients [35]. It is also important to 
appreciate that pathogenic T-cells may not always resemble conventional, antigen-
activated T-cells. For example, some T-cells in RA appear to be cytokine- rather than 
antigen-activated [36]. There is also good evidence that ‘exhausted’ or senescent, 
CD28-, T-cells play an important role in RA pathogenesis [37], and other unusual 
subsets of T-cells have also been identified [38,39]. In general these atypical T-cells 
appear to have autoreactive potential and are therefore legitimate targets. 
Increasingly their biology is becoming elucidated, revealing novel pathways and 
molecules for therapeutic intervention [40-42]. 
 
SMALL MOLECULE INHIBITORS OF T-CELLS 
A number of conventional disease-modifying anti-rheumatic drugs interfere with T-
cell function. For example, ciclosporin is a calcineurin antagonist. Interleukin-2 
production is central to T-cell activation and proliferation, and calcineurin is a critical 
upstream signalling intermediary. Consequently, ciclosporin inhibits IL-2 production 
and is a potent immunosuppressive drug, widely used in solid organ and bone 
marrow transplantation to treat graft rejection and graft-versus-host disease. It was 
introduced as a treatment for RA during the early 1990s, its use underpinned by 
clinical trials that demonstrated both reduction in symptoms and signs as well as 
slowing of radiographic progression [43-45]. It continues to be used as a second or 
third-line DMARD, particularly in combination regimes [46,47], but dose-limiting 
toxicity has restricted its widespread application. Renal toxicity, in particular, has 
been problematic [48]. 
 
Leflunomide inhibits dihydroorate dehydrogenase (DHODH), a central enzyme in de 
novo pyrimidine biosynthesis, and a pathway that is important for the proliferation of 
activated T-cells [49]. Clinical trials have shown an acceptable safety profile and 
efficacy that matches methotrexate (MTX) and sulphasalazine, which includes 
retardation of joint damage [50,51]. It has a long half life and slow onset of action but 
regimes that incorporate a loading dose tend to be associated with a higher 
incidence of toxicity, particularly gastro-intestinal. Regular monitoring of blood counts, 
liver function and blood pressure is required during routine use. In cases of toxicity, 
the clearance of leflunomide can be accelerated with cholestyramine.  
 
MTX is the most widely prescribed drug for RA. Even at the doses used to treat RA it 
inhibits purine and pyrimidine synthesis but only for a brief time after each 
administration. Therefore although MTX does inhibit antigen-induced T-cell 
proliferation temporarily after each dose, it is uncertain what contribution (if any) this 
makes to its therapeutic efficacy [52]. 
 
THE PAST: THERAPEUTIC TOLERANCE AND THE HISTORY OF T-CELL 
TARGETING IN RA 
The discovery of monoclonal antibodies (mAbs) in the 1970s was followed by a 
period of intense investigation of their potential to prevent and ameliorate undesirable 
immunopathology. The rationale was that helper T-cells were the ‘master regulators’ 
of immune responses but that their programming could be plastic. Subsequent 
studies, using mAbs to target cell surface antigens, demonstrated their potent ability 
in this regard. For example, it was possible to generate transplant tolerance (the 
acceptance of a foreign organ graft without a requirement for chronic 
immunosuppression) by targeting CD4+ (± CD8+) T-cells for a brief period around 
the time of transplantation [53]. Of more relevance to rheumatology, autoimmunity 
could be prevented and ‘switched off’ using similar regimes [54]. Initial regimes 
utilised depleting mAbs but even more powerful effects were demonstrated with non-
depleting mAbs, including the emergence of regulatory T-cells. The associated 
phenomena of linked and bystander suppression, whereby induced tolerance to a 
particular peptide extended to other epitopes derived from the same protein and even 
to peptides derived from distinct proteins in the same microenvironment, promised 
powerful and revolutionary therapies for autoimmunity. A number of rules and models 
were generated to explain the experimental findings although the underlying cell 
biology was not elucidated. Of relevance to human disease, a greater bulk of 
pathogenic T-cells required more intensive immunomodulatory regimes. In the 
transplant setting not all MHC barriers were amenable to tolerance induction, and 
others required combinations of depleting and non-depleting mAbs administered over 
several weeks [55]. Similarly some autoimmune models (eg murine SLE) appeared 
more amenable to immune modulation therapy than others (eg. collagen-induced 
arthritis). A number of distinct T-cell surface molecules were permissive for tolerance 
induction, and the ‘war analogy’ model postulated that treatment merely ‘blindfolded’ 
pathogenic T-cells, preventing their interaction with neighbours, resulting in a default 
state of self-tolerance and regulatory T-cell generation [56]. 
 
The first biological therapies to be applied to RA targetted T-cells. These ranged from 
lymphocytotoxic depleting therapies such as CAMPATH-1H (alemtuzumab) to non-
depleting CD4 mAbs. This area has recently been reviewed [57] and will not be 
covered in detail. However, three key limitations hampered development of these 
therapies.  
 
1. It was assumed that lymphocyte depletion would be followed by full 
reconstitution with a newly generated repertoire. Indeed, a driving force 
behind this mode of therapy was the concept of an emerging, self-tolerant, 
immune system. The adult human immune system was severely limited in its 
capacity for reconstitution, however, particularly in RA. Lymphocyte depletion 
was followed by long-lasting lymphopenia, although without clear detriment 
[58,59]. A number of potential contributors to poor reconstitution have been 
identified subsequently [38,60].  
2. The in vivo biological activity of mAbs that targeted human T-cells proved 
extremely difficult to predict. The possible consequences of binding included 
depletion, modulation, shedding, activation and coating; the precise outcome 
was determined by features of the mAb and its target that were only partly 
understood. In vitro assays proved to be poor models of the in vivo  
(micro)environment and the information provided by animal models was 
severely limited by inter-species differences in both target antigen and Fc-
gamma receptors (FcγR) [61]. These limitations were vividly and 
catastrophically illustrated by the phase I study of TGN1412, in which 6 
healthy volunteers received a T- cell ‘superagonist’ mAb that had been 
administered safely to cynomolgus monkeys. The life-threatening cytokine 
storm experienced by the human volunteers was difficult to replicate in vitro 
even after the event and has resulted in further safeguards during mAb 
development [62,63].  
3. The aforementioned limitations of animal and in vitro testing meant that the 
tolerogenic potential of mAbs could not be predicted. Furthermore, because 
the cell biology of therapeutic tolerance was not understood, biomarkers of 
therapeutic tolerance induction were not available. Compounding these 
limitations, a tolerogenic mAb was not necessarily anti-inflammatory, and a 
lack of short-term improvement in a disease like RA need not represent 
treatment failure – yet anti-inflammatory drugs could antagonise tolerogenic 
effects [64,65]. Hence without biomarkers to guide dose and duration of 
therapy, therapeutic tolerance was truly a ‘holy grail’, success as likely to 
represent luck as judgement. It is quite plausible that potentially tolerogenic 
drugs were prematurely and inappropriately abandoned and, when truly non-
depleting mAbs were finally developed, plans to administer these for 
prolonged periods at high dosage were complicated by unpredicted side 
effects such as skin rashes [66]. Inflammation itself is likely to inhibit tolerance 
generation, and other regimes combined biologic agents to suppress 
inflammation prior to the administration of anti-T cell therapy [67]. 
 
These limitations curtailed the initial development of T-cell mAbs in RA. Indeed, the 
prevailing sentiment was that biological therapies in general could have limited utility 
in autoimmunity and the entire therapeutic area was endangered. Fortunately the 
parallel development of TNFα blockade provided much needed optimism. 
 
THE PRESENT: COSTIMULATION BLOCKADE  
It was, of course, possible that CD4 was not a tractable target in human RA or that 
RA was not susceptible to therapeutic tolerance induction. Certainly late, refractory 
disease (the patient group chosen for many clinical trials) presented several 
undesirable characteristics such as high levels of inflammation, prior therapy with 
multiple drugs and, potentially, intrinsic defects of immune regulation. However, a 
(then) recently described concept suggested a key event in T-cell activation to be the 
interaction of T-cell co-stimulatory molecules with their ligands on antigen presenting 
cells (APCs). Disruption of these interactions not only prevented T-cell activation but 
was also associated with tolerance induction [68]. The best known costimulatory 
molecule/ligand interactions were those between CD28, and B7.1 and B7.2 (now 
known as CD80 and CD86), and CD40 with CD40L. Animal models again 
emphasised the potential potency of so-called costimulation blockade [69,70]. Early 
trials of a CD40L mAb in patients with SLE provided encouraging efficacy signals but 
were complicated by unexpected thromboembolic events which halted further 
development [71]. The CD28 interaction with CD80/86 proved more amenable to 
therapeutic intervention, however. The strategy that was finally adopted utilised a 
fusion protein between CTLA4 and a modified human IgG1 Fc, CTLA4-Ig. CTLA4 is 
a negative regulator of T-cells that is up-regulated after T-cell activation. It has a 
higher affinity for CD80/86 than CD28, thereby displacing it and acting as a T-cell 
‘brake’. CTLA4-Ig retains the affinity of CTLA4 and therefore interrupts the 
costimulatory signal, preventing and potentially reversing T-cell activation. The Fc 
modification prevents complement activation, potentially reducing the incidence of 
infusion reactions [72]. 
 
Abatacept is administered by intravenous infusion. Loading doses on days 1, 15 and 
29 are followed by monthly infusions of approximately 10mg/kg, a dose that showed 
significant efficacy at the 6 month primary endpoint of a phase IIB study [74]. 
Responses to placebo and 10mg/kg abatacept respectively were 35% and 60% 
(ACR20); 12% and 36% (ACR50); and 2% and 16% (ACR70). Quality of life also 
improved with abatacept and benefits were sustained at 12 months, including 
significantly higher rates of DAS28 remission compared to placebo (10% vs 35%), 
and clinically relevant improvements in function [75]. Two phase III clinical trials of 
abatacept have confirmed these benefits. In the Abatacept In Methotrexate 
inadequate responders (AIM) trial ACR20, 50 and 70 response rates at 12 months 
were superior with abatacept compared to placebo: 73% vs 40%, 48 vs 18% and 
29% vs 6% respectively [76]. There were also improvements in function (HAQ-DI) 
and health-related quality of life (SF36) [77]. Abatacept therapy was additionally 
associated with a slowing of radiographic progression at 2 years, and improvement in 
symptoms and signs has now been documented to 3 years [78,79]. The Abatacept 
Trial in Treatment of Anti-TNF INadequate responders (ATTAIN) study confirmed the 
benefits of abatacept in patients with a current or previous inadequate response to 
TNFα blockade [80][81]. Efficacy of abatacept is sustained for at least 2 years in this 
patient group [82]. 
 
In the AIM study, overall adverse event (AE) rates were similar with abatacept or 
placebo although abatacept recipients had a higher incidence of acute infusion 
reactions (8.8 vs 4.1%) and pre-specified serious infections (2.5 vs 0.9%) [76]. In 
ATTAIN acute infusion reactions and infections were non-significantly higher in the 
active treatment arm but rates of serious adverse events (SAEs) and serious 
infections were equivalent to the rate with placebo [80]. Therefore, to date abatacept 
has demonstrated an acceptable safety profile when added to MTX or other 
conventional DMARDs, and its immunogenicity has been low [83,84]. In particular 
there does not appear to be a significantly enhanced risk of infection or malignancy. 
In the Abatacept Study of Safety in Use with other RA thErapies (ASSURE) trial, 
however, its combination with TNFα blockade led to a doubling of SAEs, with no 
corresponding improvement in efficacy [85]. Even when combined at the lower dose 
of 2mg/kg with etanercept the SAE rate was 16.5% (abatacept plus etanercept) vs 
2.8% (abatacept plus placebo), and serious infection rate 3.5% vs 0% respectively 
[86]. Therefore abatacept should not, at this time, be combined with other biologic 
therapies.  
 
.Abatacept is now licensed for the treatment of RA. The quality of response may 
increase with time on the drug, and long-term extension studies suggest a relatively 
low rate of secondary treatment failure. There is a sustained rate of response at 2 
and 3 years by intention-to-treat analysis and, intriguingly, an apparent continued 
improvement in response rate according to the less robust ‘as-observed’ analysis 
[82]. Radiographic studies also suggest further slowing of joint damage in the second 
year of therapy [78]. Whilst these data may suggest a gradual ‘switching off’ of 
disease, only time can tell whether abatacept induces true tolerance – in which case 
a patient in remission on abatacept should be able to stop therapy without loss of 
benefit.  
 
Recently, the ATTEST trial (Abatacept or infliximab versus placebo, a Trial for 
Tolerability, Efficacy and Safety in Treating RA) provided an indirect comparison of 
treatment with infliximab and abatacept [87]. Patients with an inadequate response to 
MTX were randomised to infliximab (3mg/kg every 8 weeks), abatacept (10mg/kg 
every 4 weeks) or placebo infusions in a double-blind, double-dummy, placebo- and 
active (infliximab)-controlled trial (MTX was continued). Both abatacept and infliximab 
were superior to placebo for efficacy throughout the 12 month study period and the 
response rates for the two active arms were similar at 6 months. By 12 months, 
however, DAS low disease activity (35.3 vs 22.4%), DAS remission (18.7  vs 12.2%), 
good EULAR response (32.0 vs 18.5%) and HAQ-DI (57.7 vs 52.7%) all favoured 
abatacept, whereas.SAEs (9.6 vs 18.2%) and serious infections (1.9 vs 8.5%) were 
more frequent with infliximab. Therefore, notwithstanding the fact that this was not 
designed as a head-to-head comparison of the biologic drugs, over the 12 month 
study period the therapeutic ratios favoured treatment with abatacept. 
 
Although marketed as a costimulation blocker, abatacept’s precise mode of action 
remains undefined. For example, some evidence suggests that binding directly to 
APCs upregulates indoleamine dioxygenase and tryptophanyl-tRNA-synthetase 
production, which will indirectly inhibit T-cell proliferation by limiting tryptophan 
availability [88]. 
 
THE FUTURE: NOVEL TREATMENT APPROACHES 
Non-mitogenic CD3 mAbs 
CD3, the ‘defining’ surface marker on T-cells, was one of the first antigens to be 
targeted for immune modulation in the 1980s. The murine mAb OKT3 was 
administered in brief courses as an immune suppressant to treat refractory rejection 
episodes, particularly in renal transplantation [89]. Although highly effective, its initial 
administration to a patient was usually complicated by a problematic ‘first-dose’ or 
‘cytokine release’ reaction. The syndrome comprised a constellation of symptoms 
ranging from high fever and chills to aseptic meningitis and respiratory distress [90]. 
Corticosteroid prophylaxis allayed the severity of the reaction but this potential 
toxicity, and the inherent immunogenicity of a murine mAb, limited the application of 
OKT3 to graft-threatening rejection episodes and its use in autoimmunity was not 
explored. 
 
First-dose reactions with OKT3 were the consequence of massive, synchronised T-
cell activation. This occurred when OKT3, bound to the T-cell surface, was ‘cross-
linked’ by FcγR-bearing accessory cells such as NK cells or monocytes. Such a 
reaction, on an even greater scale, underpinned the disastrous reaction to TGN-1412 
referred to earlier [62]. Because the interaction between mAb and FcγRs is 
predicated by a small number of critical residues in the mAb Fc, genetic engineering 
techniques have been used to create non-FcγR binding (non-activating or non-
mitogenic) CD3 mAbs. In animal models, equivalent mAbs are potent 
immunodulators without invoking cytokine release. For example, autoimmune 
diabetes was permanently switched off, in association with regulatory T-cell 
generation [91]. As with CD4 mAbs, the cell biology of tolerance induction in this 
setting is incompletely understood. Some theories suggest a requirement for partial 
T-cell signalling and activation, whereas others imply a ‘blindfolding’ and 
environmental isolation of the T-cell by mAb coating [92]. 
 
Three non-activating CD3 mAbs have entered the clinic in non-rheumatological 
diseases: teplizumab, otelixizumab and visilizumab. Teplizumab, a direct descendent 
of OKT3, and visilizumab have two amino acid alterations in the Fc, that reduce FcγR 
binding. In contrast otelixizumab incorporates a single mutation, that prevents N-
linked glycosylation of the Fc (glycosylation being essential for FcγR binding and 
complement activation). Like OKT3 before them, both teplizumab and the aglycosyl 
otelixizumab have been used as immunosuppressants to reverse acute allograft 
rejection [93,94]. More impressively, brief courses of therapy in type I diabetes (T1D) 
resulted in disease stabilisation for over two years [95-97]. Repeated courses have 
been administered with some evidence that therapy induces favourable 
immunoregulatory mechanisms [98,99]. In a phase I/II study of psoriatic arthritis, 8-10 
days of treatment with teplizumab was followed by a reduction in tender and swollen 
joints for at least 3 months [100]. First-dose reactions were reported to be absent or 
mild in these studies. Inflammatory bowel disease and graft versus host disease 
have been the disease targets for visilizumab. In a phase I study in steroid-refractory 
ulcerative colitis, doses of 10-15µg/kg were associated with clinical benefit although 
mild to moderate cytokine release was observed even at these low doses [101,102].  
 
Other T-cell surface molecules 
A variety of other T-cell mAbs are approved for the treatment of non-rheumatological 
indications. Efalizumab is a humanised CD11a mAb that blocks interactions between 
the integrin LFA-1 and cell adhesion molecule ICAM-1. In this way efalizumab inhibits 
tight lymphocyte adhesion to inflamed endothelium [103]. Administered by weekly 
subcutaneous injection, it is licensed for the treatment of moderate to severe 
psoriasis, and has also shown encouraging data in severe atopic dermatitis 
[104,105]. Alefacept is a fusion protein between the extracellular domain of LFA-3 
and human IgG1 Fc. Because CD2, the ligand for LFA-3, is expressed more densely 
on memory T-cells alefacept has the potential advantage of preferentially targeting 
this disease-associated T-cell subset. The CD2/LFA-3 interaction provides 
costimulation to T-cells but this mAb is also cytotoxic, therapy reducing the number of 
circulating memory T-cells. As with many biological therapies, the most relevant 
mechanism of action is uncertain [106,107]. However, administered by weekly 
intramuscular injection, it is approved for the treatment of moderate to severe plaque 
psoriasis and a recent clinical trial demonstrated efficacy in psoriatic arthritis 
[108,109]. Natalizumab, a mAb of human IgG4 isotype, targets the α4 integrin chain 
and blocks the α4β1/VCAM-1 interaction at inflammatory sites as well as the 
α4β7/MADCAM-1 interaction at mucosae. In both locations therapy interferes with 
lymphocyte trafficking although a recent publication also highlights its ability to 
mobilise haematopoietic stem cells [110]. It is approved for the treatment of multiple 
sclerosis (MS) and is also effective for remission induction in Crohn’s disease 
[111,112]. Development of natalizumab for MS was temporarily suspended following 
reports of progressive multifocal leucoencephalopathy in three recipients but it has 
now been reinstated under a restricted programme [113].  
 
Peptide therapy 
An important qualification to the treatments discussed so far is their potential to target 
most or all T-cells, which may increase the risk of non-specific immune suppression 
associated with their use. Regulatory T-cell subsets will also be targeted, with 
potentially beneficial (as postulated for non-activating CD3 mAbs) or detrimental 
consequences. The ideal immunomodulatory therapy may, therefore, be one that 
specifically targets autoreactive T-cells. This concept has been proven repeatedly in 
animal models but these are generally induced autoimmune diseases of inbred 
mouse strains where, by definition, the autoantigen is known. In contrast pathogenic 
T-cell clones have proved elusive in RA. Furthermore, and not surprisingly for an 
outbred population, several autoantigens have been identified with only partial 
overlap of autoreactivity between patients. However, antigen-specific therapies have 
produced encouraging data in human allergic diseases and in T1D. 
 
Fel d 1 is an antigen present in animal dander that is an allergen in atopic asthma. In 
cat allergic subjects, six fortnightly intradermal injections of a Fel d 1 peptide mixture 
improved symptoms and quality of life. There was an associated reduction in the late 
asthmatic reaction and cutaneous hypersensitivity to whole cat dander [114]. In vitro 
data showed reduced TH1 and TH2 responses and the induction of an IL-10-
secreting, suppressive, regulatory cell population [115]. Mechanistic studies suggest 
that the dose and length of peptide are important determinants of peptide therapy 
efficacy but optimal dosing regimes have yet to be defined [116]. In recent onset 
T1D, three subcutaneous injections of a modified peptide derived from human heat 
shock protein 60 (hsp60), spaced over 6 months, led to preservation of insulin 
secretion when compared to placebo, and improved metabolic control lasting for 18 
months [117,118]. There was associated ex vivo evidence for TH2 immune deviation. 
A small, dose-ranging study confirmed the beneficial effects on pancreatic function 
but could not reproduce the benefit in terms of insulin requirement or metabolic 
control [119].  
 
Hsp peptides have also been studied as immunomodulators in juvenile idiopathic 
arthritis (JIA). A series of peptides derived from human and bacterial hsp60, 
predicted by computer algorithm to bind a range of human DR subtypes, were 
incubated in vitro with PBMC from JIA patients and healthy controls. Higher T-cell 
proliferative responses were observed using JIA PBMC, in association with a higher 
IL-10:IFNγ ratio in culture supernatants [120]. A further in vitro study suggested that, 
in JIA, the quality of the T-cell response to peptides derived from the dnaJ hsp 
depended on their origin: bacterially-derived peptides evoked a pro-inflammatory 
response whereas human sequences evoked regulatory responses [121]. In a 
related study, RA patients with in vitro T-cell reactivity to a peptide derived from 
bacterial dnaJ (with sequence homology to the shared epitope) were treated orally 
with this peptide for 6 months. No clinical outcomes were reported but treatment was 
associated with reduced in vitro T-cell proliferation to the peptide, with reduced 
secretion of IFNγ, TNFα, and IL-2 but increased IL-4 and IL-10. FoxP3 expression 
was also increased in post-treatment blood, possibly suggestive of an 
immunoregulatory effect of treatment [122].  
 
The precise role of hsps in autoimmunity remains unclear, and therapies such as 
those described above may have complex modes of action. For example, the hsp 
peptide utilised in the T1D studies signals via TLR2 as well as presumably binding 
the TCR. The former activity is associated with both a reduction in chemokine-
induced chemotaxis and may also enhance regulatory T-cell function [123,124]. As 
alluded to earlier in this article, the cartilage glycoprotein hGP39 has been implicated 
as an RA autoantigen [35,125]. An altered peptide ligand (APL) has been identified, 
based on an immunodominant hGP39 epitope [126]. APLs can act as TCR 
antagonists, and are therefore of potential therapeutic benefit. A TCR antagonist 
administered to multiple sclerosis patients resulted in disease flares, however, due to 
the unpredicted recruitment of novel, autoreactive T-cell specificities [127]. The 
hGP39 APL has a distinct, non-classical, design and should not have this potential. 
Phase I RA studies have also studied nasal administration of an hGP39-derived 
peptide as well as infusions of a soluble complex of HLADR4 with a different hGP39-
derived peptide [128,129]. 
 
Cellular therapies 
Regulatory T-cells are now recognised and, to some extent, validated as important 
players in the maintenance of immune tolerance and the control of immunopathology. 
There are several regulatory T-cell subsets, some induced and others naturally 
occurring [130]. The best characterised are the thymically-derived, FoxP3-expressing 
‘natural’ regulatory T-cells (Treg) [131]. Inherited deficiency of this subset is associated 
with a range of autoimmune phenomena in animals and in man [132]. Furthermore, 
in animal models, manipulation of Treg numbers and/or function can influence 
susceptibility to autoimmunity and have profound effects in established disease. 
Critically, adoptive transfer of these cells can be an effective therapy, and some of 
the treatments discussed earlier in this review may influence Treg function [133]. The 
situation in human autoimmunity is less clear but there are now a number of 
publications attesting to a defect of Treg number or function in these conditions, 
including rheumatoid arthritis [130,134-136]. Indeed, TNFα blockade appears to 
boost Treg function in RA, in addition to inducing development of a novel regulatory T-
cell subset [137,138]. Furthermore, expansion of Treg may underlie the long-term 
responses to autologous stem cell transplantation observed in juvenile idiopathic 
arthritis [139]. In animal models T-cell superagonists, that activate T-cells through 
CD28, expand Treg with beneficial effects in a range of immune pathologies 
[140,141]. Unfortunately, it was one such mAb (TGN1412) that produced a massive 
first-dose cytokine storm with serious sequelae for the participants in a phase I study 
[62]. As with OKT3, modifications to the mAb Fc could almost certainly produce a 
safer product that retains efficacy, but such an approach is unlikely in the near future. 
Another novel approach for boosting Treg function is to combine strategies, such as 
tolerogenic peptide administration with non-mitogenic anti-CD3 or TNFα blockade 
[142,143]. 
 
Ultimately it may be possible to treat human autoimmunity by the isolation, expansion 
and reinfusion of Treg from patients. Such an approach is effective in animal models 
although the most potent effects occur when cellular expansion involves the use of a 
relevant autoantigen [144]. The low frequency of Treg in peripheral blood, combined 
with their lack of a unique surface phenotype, further complicates this approach and 
it may prove more feasible to generate regulatory T-cells by pharmacological 
manipulation of peripheral blood [145]. Autologous cellular therapy requires GMP 
facilities and would be significantly more expensive than even current biologic 
therapies. The overall feasibility and acceptability of this approach will depend 
strongly on the induction of a powerful and reproducible immunomodulatory effect 
[146,147].  
 
Recently, a potentially beneficial immunomodulatory response was obtained by 
vaccinating RA patients with expanded, activated and irradiated autologous synovial 
fluid T-cells [148]. This was an open study of 16 patients and the reported efficacy 
must be confirmed in a formal trial. Nonetheless treatment was associated with 
expansion of CD4+_and CD8+ T-cells, many of which expressed the Vβ2 T-cell 
receptor chain. Some were anti-idiotypic, responding specifically to vaccine T-cells 
with production of IL-10 (CD4+ cells) or granzyme B (CD8+ cells). A broader 
regulatory response, however, was directed towards activated T-cells in general, 
specifically against peptides derived from the IL2 receptor alpha chain (so-called anti-
ergotypic T-cells). The latter response may be critical to harness in a disease where 
the precise autoantigen and pathogenic T-cell clones are not readily identifiable, 
perhaps explaining why a previous attempt at T-cell vaccination using TCR-derived 
peptides has not been pursued [149]. 
 
CONCLUSIONS 
Over the past 20 years, the development of T-cell targeted therapies for 
autoimmunity has come full circle. The pessimism that surrounded early clinical trials 
of CD4 mAbs has been replaced by optimism surrounding costimulation blockade 
and more novel approaches to immunomodulation. In large part this new confidence 
has been fuelled by an enhanced understanding of immune regulation, and 
particularly of regulatory T-cell function. However, we continue to require better 
biomarkers of tolerance induction in order to exploit these novel modalities to their full 
potential. We are also better at recognising and defining autoantigens, potentially 
moving us closer to our ultimate goal of inducing antigen-specific tolerance via safe 
and innocuous treatments. Ultimately established RA remains a complex disease, 
and it remains to be seen whether any immunomodulatory therapies will be 
sufficiently potent to correct many years of cumulative immune dysregulation and 
pathology. As safer treatments and more informative biomarkers allow us to move 
into earlier disease, however, the potential for cure should become a reality. 
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KEY MESSAGES 
1. Accumulating evidence incriminates T-cells in RA pathogenesis. 
2. Co-stimulation blockade is efficacious in RA. 
3. Better biomarkers and novel immunomodulatory strategies may soon enable us to 
‘switch off’ autoimmunity. 
